Related Experiment Video

Updated: Aug 22, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in

Richard Kelly1,2, Andrew Jensen3, Nathasha Karunaratna4

  • 1Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic., Australia.

BJU International
|November 13, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Experiment Videos

Last Updated: Aug 22, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.4K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.4K

Articles linked to this work by shared authors, journal, and citation graph.

Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

NanoString profiling of DNA repair and apoptosis genes in testicular germ cell tumours with divergent chemotherapy outcomes.

Therapeutic advances in medical oncology·2026

Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer.

Asia-Pacific journal of clinical oncology·2026

Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.

Asia-Pacific journal of clinical oncology·2026

Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC).

Clinical genitourinary cancer·2026

A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Impact of operative time on complications after PCNL in the elderly (aged ≥70 years): the Safety and Efficacy of Nephrolithotomy in Older patients undergoing PCNL (SENIOR-PCNL) study.

BJU international·2026

Patient-reported outcomes after open and robotic radical prostatectomy: a New Zealand registry study.

BJU international·2026

The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer.

BJU international·2026

The role of PSA density in the follow up of men with a negative MRI in the Göteborg-2 trial.

BJU international·2026

Endoscopic kidney-sparing surgery for upper tract urothelial carcinoma in patients with a solitary kidney.

BJU international·2026

EXPRESSION OF CONCERN: Small Interference RNA Targeting Heat-Shock Protein 27 Inhibits the Growth of Prostatic Cell Lines and Induces Apoptosis via Caspase-3 Activation In Vitro.

BJU international·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us